Login / Signup

Cost and availability of novel cell and gene therapies: Can we avoid a catastrophic second valley of death?: Can we avoid a catastrophic second valley of death?

Michele De LucaGiulio Cossu
Published in: EMBO reports (2023)
Advanced gene and cellular therapies risk a second "valley of death" due to their high costs and low patient population. As these are life-saving therapies, measures are urgently needed to prevent their withdrawal from the market.
Keyphrases
  • copy number
  • genome wide
  • genome wide identification
  • cell therapy
  • health insurance
  • dna methylation
  • genome wide analysis